

AUG. 01 '2002 20:31

HOLLAND & KNIGHT LLP

One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400

404-817-8500
FAX 404-881-0470
http://www.hklaw.com

Bradenton
Chicago
Fort Lauderdale
Jacksonville
Lakeland
Los Angeles
Melbourne
Miami
New York

International Offices:
Cancun
Helsinki
Mexico City
Rio de Janeiro

#5086 P.001
Providence
San Antonio
San Francisco
Seattle
St. Petersburg
Tallahassee
Tampa
Washington, D.C.
West Palm Beach

Sao Paulo
Tel Aviv
Tokyo

FAX RECEIVED

AUG 02 2002

FACSIMILE

GROUP 1600

TO:

| | | |
|------------------------|---------------------------------------|--------------------|
| Group 1600 After Final | Assistant Commissioner for Patents | 703-872-9307 |
| NAME | COMPANY/FIRM | FAX NUMBER |
| Washington | DC | 703-308-0198 |
| CITY | STATE | (TELEPHONE NUMBER) |

OFFICIAL

FROM:

| | | |
|-----------------|--------------|-------------------------------------|
| Patrea L. Pabst | 404-817-8473 | 20 |
| NAME | TELEPHONE | TOTAL PAGES (Including Cover Sheet) |

FOR THE RECORD:

DATE: June 7, 2002 URGENCY: ☐ SUPER RUSH ☐ RUSH ☐ REGULAR

FAXED BY: FILE #: 077818 /00008/ CLIENT NAME: IT 106

CONFIRMED: ☐ YES ☐ NO NAME: TIME:

If you did not receive all of
the pages or find that they
are illegible, please call
(404) 817-8500

CONFIDENTIALITY NOTICE: This facsimile, along with any documents, files, or attachments, may contain information that is confidential, privileged, or otherwise exempt from disclosure. If you are not the intended recipient or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, printing, distribution or use of any information contained in or attached to this facsimile is strictly prohibited. If you have received this facsimile in error, please immediately notify us by facsimile or by telephone collect at the numbers stated above, and destroy the original facsimile and its attachments without reading, printing, or saving in any manner. Your cooperation is appreciated. Thank you.

MESSAGE:

Applicants: Elizabeth M. Denholm, Yong-Qing Lin, and Paul J. Silver

Serial No.: 09/715,965 Art Unit: 1651

Filed: November 17, 2000 Examiner: Meller, M.

For: **ATTENUATION OF TUMOR GROWTH, METASTASIS AND ANGIOGENESIS**

ATL1 #511177 v1

**CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL**Submit an original, and a duplicate for fee processing.
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

CHECK BOX, if applicable:

☐ DUPLICATE

Address to:

Assistant Commissioner for Patents
Box CPA
Washington, DC 20231Attorney Docket No.
of Prior Application

IT 106

First Named Inventor

Elizabeth M. Denholm

Examiner Name

M. Meller

Group Art Unit

1651

Express Mail Label No.

This is a request for a ☐ continuation or ☐ divisional application under 37 CFR 1.53(d),
(continued prosecution application (CPA)) of prior application number 09 / 715,965
ATTENUATION OF TUMOR GROWTH, METASTASIS
filed on 11/17/00, entitled AND ANGIOGENESIS

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application. See "Request for Continued Examination Practice changes to and Provisional Application Practice," Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office (Apr. 11, 2000).

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(e).

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

1. ☐ Enter the unentered amendment previously filed on _____
under 37 CFR 1.116 in the prior nonprovisional application.
2. ☒ A preliminary amendment is enclosed.
3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
 - a. ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application:

 - b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5. Information Disclosure Statement (IDS) is enclosed:
 - a. ☐ PTO-1449
 - b. ☐ Copies of IDS Citations

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box CPA, Washington, DC 20231.

PTO/SB/29 (08-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| CLAIMS | (1) FOR | (2) NUMBER FILED | (3) NUMBER EXTRA | (4) RATE | (5) CALCULATIONS |
|---|---------|------------------|------------------|-------------------------------|------------------|
| TOTAL CLAIMS (37 CFR 1.16(c) or (f)) | | 18 -20* = | 0 | x \$ _____ = | \$ -0- |
| INDEPENDENT CLAIMS (37 CFR 1.16(b) or (f)) | | 1 -3** = | 0 | x \$ _____ = | -0- |
| MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d)) | | | | + \$ 270.00 = | -0- |
| | | | | BASIC FEE (37 CFR 1.18) | 740.00 |
| | | | | Total of above Calculations = | 740.00 |
| Reduction by 50% for filing by small entity (Note 37 CFR 1.27). | | | | | 370.00 |
| * Reissue claims in excess of 20 and over original patent. ** Reissue independent claims over original patent. | | | | TOTAL = | 370.00 |

6. ☒ Small entity status: Applicant claims small entity status. See 37 CFR 1.27.7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 50-1868:

- a. ☒ Fees required under 37 CFR 1.16.
 b. ☒ Fees required under 37 CFR 1.17.
 c. ☐ Fees required under 37 CFR 1.18.

8. ☐ A check in the amount of \$ _____ is enclosed.9. ☐ Payment by credit card. Form PTO-2038 is attached.10. ☐ Applicant requests suspension of action under 37 CFR 1.103(b) (fee under 37 CFR 1.17(i) enclosed).11. ☐ New Attorney Docket Number, if desired _____

(Prior application Attorney Docket Number will carryover to this CPA unless a new Attorney Docket Number has been provided herein.)

12. a. ☒ Receipt For Facsimile Transmitted CPA (PTO/SB/29A)b. ☐ Return Receipt Postcard (Should be specifically itemized, See MPEP 503)13. ☐ Other: _____**NOTE:**

The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.

14. NEW CORRESPONDENCE ADDRESS☐ Customer Number or Bar Code Labelor ☐ New correspondence address below

(Insert Customer No. or Attach bar code label here)

| | | | | | |
|---------|--|-----------|----------------|----------|----------------|
| Name | Patrea L. Pabst | | | | |
| | HOLLAND & KNIGHT LLP | | | | |
| Address | One Atlantic Center | | | | |
| | 1201 West Peachtree Street, Suite 2000 | | | | |
| City | Atlanta | State | GA | Zip Code | 30309-3450 |
| Country | United States | Telephone | (404) 817-8473 | Fax | (404) 817-8588 |

15. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type): Patrea L. Pabst

Signature

Registration No. (Attorney/Agent)

31,284

Date

August 1, 2002


PTO/SB/97 (12-97)
Approved for use through 8/30/00. OMB 0851-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S.S.N. 09/715,965
Filed November 17, 2000
CPA, Amendment, Petition for
Extension of Time

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
Patent and Trademark Office

on August 1, 2002
Date


Signature

Patrea Pabst
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify
each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case.
Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office,
Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,
Washington, DC 20231.

PTO/SB/29A (8/98)
Approved for use through 09/30/2000, OMB 0651-9032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|--|---|---|
| <p>If this RECEIPT is included with a request for a CPA filed by facsimile transmission, it will be date stamped and mailed to the ADDRESS in Item 1.</p> | | <p align="center">RECEIPT FOR FACSIMILE TRANSMITTED CPA</p> <p align="center"><i>(To accompany a request for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) filed by facsimile transmission)</i></p> |
| <p>1. ADDRESS</p> | <p>Applicant's Mailing Address for this receipt <i>must</i> be CLEARLY PRINTED or TYPED in the box below.</p> <p>Patrea L. Pabst HOLLAND & KNIGHT LLP One Atlantic Center 1201 West Peachtree Street, Suite 2000 Atlanta, GA 30309-3400</p> | |
| <p>NOTE: By this receipt, the PTO (a) acknowledges that a request for a CPA was filed by facsimile transmission on the date stamped below by the PTO and (b) verifies only that the application number provided by the applicant on this receipt is the same as the application number provided on the accompanying request for a CPA. This receipt CANNOT be used to acknowledge receipt of any paper(s) other than the request for a CPA.</p> | | |
| <p>2. APPLICATION IDENTIFICATION: <i>(Provide at least enough information to identify the application)</i></p> <p>a. For prior application</p> <p>Application No: 09/715,965</p> <p>Filing Date: November 17, 2000</p> <p>Title: ATTENUATION OF TUMOR GROWTH, METASTASIS AND ANGIOGENESIS</p> <p>Attorney Docket No: IT 106</p> <p>First Named Inventor: Elizabeth M. Denholm</p> <p>b. For instant CPA application</p> <p>New Attorney Docket No: _____ <i>(If applicable)</i></p> | | |
| <p>The PTO date stamp, which appears in the box to the right, is an acknowledgement by the PTO of receipt of a request for a CPA filed by facsimile transmission on the date indicated below.</p> | | <p align="center"><i>(THIS AREA FOR PTO DATE STAMP USE)</i></p> |
| <p>PTO HANDLING INSTRUCTIONS:</p> <p>Please stamp area to the right with the date the complete transmission of the request for a CPA was received in the PTO and also include the PTO organization name that provided the date stamp (stamp may include both items). Verify that the application number provided by applicant on this receipt is the same as the application number provided by applicant on the request for a CPA accompanying this receipt. If there is an inconsistency between the application number provided on this receipt and the request for a CPA, strike through the inconsistent application number provided on this receipt and insert the correct application number, if possible. Then place in a window envelope and mail.</p> | | |

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Received from < > at 8/1/02 8:48:22 PM [Eastern Daylight Time]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elizabeth M. Denholm, Yong-Qing Lin, and Paul J. Silver

Serial No.: 09/715,965

Art Unit: 1651

Filed: November 17, 2000

Examiner: M. Meller

For: ATTENUATION OF TUMOR GROWTH, METASTASIS AND
ANGIOGENESISAssistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

Sir:

Responsive to the Office Action mailed April 1, 2002, please amend the application as follows. A Petition for an Extension of Time for one month, up to and including August 1, 2002, and the appropriate fee for a small entity, are enclosed. Also enclosed is a request for filing a Continuing Prosecution Application.

In the Claims

who has cancer

1. (twice amended) A method to decrease [tumor growth] angiogenesis comprising administering to [tumors in] a site in an individual in need of treatment thereof an effective amount of a purified glycosaminoglycan degrading enzyme to decrease angiogenesis [and thereby reduce tumor growth] at the site, wherein the decrease in angiogenesis is measured as a decrease in endothelial cell proliferation or a decrease in the formation of capillary-like structures.

Chondroitinase AC

interest
to
applicat
of
enzyme